Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Operating Margin (2021 - 2025)

Historic Operating Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 315927.27%.

  • Allogene Therapeutics' Operating Margin rose 143793900.0% to 315927.27% in Q1 2024 from the same period last year, while for Dec 2024 it was 1241813.64%, marking a year-over-year decrease of 8968273200.0%. This contributed to the annual value of 1241813.64% for FY2024, which is 8968273200.0% down from last year.
  • As of Q1 2024, Allogene Therapeutics' Operating Margin stood at 315927.27%, which was up 143793900.0% from 405280.95% recorded in Q4 2023.
  • Allogene Therapeutics' Operating Margin's 5-year high stood at 2.26% during Q4 2021, with a 5-year trough of 405280.95% in Q4 2023.
  • Moreover, its 4-year median value for Operating Margin was 286345.45% (2023), whereas its average is 232707.56%.
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Operating Margin was 417170500bps (2022), while the steepest drop was 2000000000bps (2022).
  • Quarter analysis of 4 years shows Allogene Therapeutics' Operating Margin stood at 2.26% in 2021, then plummeted by -16431036bps to 370750.0% in 2022, then dropped by -9bps to 405280.95% in 2023, then increased by 22bps to 315927.27% in 2024.
  • Its Operating Margin was 315927.27% in Q1 2024, compared to 405280.95% in Q4 2023 and 286345.45% in Q3 2023.